Table 2.
PPTF group descriptive statistics and patient outcomes
| mean | Overalla (n = 53) | Naïve (n = 16) | Erenumab (n = 16) | Galcanezumab (n = 17) | p valueb |
|---|---|---|---|---|---|
| Age, years, mean (SD) | 36.42 (10.55) | 33.25 (9.36) | 38.56 (10.28) | 36.24 (10.71) | 0.174 |
| Age of migraine onset, mean (SD) | 29.43 (8.74) | 28.42 (6.42) | 26.77 (7.79) | 31.67 (9.80) | 0.702 |
| Sex, female, n (%) | 40.00 (75.47) | 11.00 (68.75) | 12.00 (75.00) | 14.00 (82.35) | 0.067 |
| Nationality, Emirati, n (%) | 46.00 (86.79) | 16.00 (100.00) | 14.00 (87.50) | 14.00 (82.35) | |
| Baseline MMD, days, mean (SD) | 12.23 (4.97) | 11.81 (4.34) | 12.00 (5.13) | 12.06 (5.92) | 0.881 |
| Month 3 MMD, days, mean (SD) | 5.21 (5.73) | 2.13 (1.86) | 5.69 (5.96) | 7.47 (6.77) | < 0.001* |
| Month 6 MMD, days, mean (SD) | 3.66 (4.21) | 3.25 (4.27) | 3.63 (4.86) | 3.82 (2.67) | 0.707 |
| Chronic migraine, n (%) | 25.00 (47.17) | 6.00 (37.50) | 6.00 (37.50) | 9.00 (52.94) | 0.582 |
| Episodic migraine, n (%) | 28.00 (52.83) | 10.00 (62.50) | 10.00 (62.50) | 8.00 (47.06) |
aStudy participants not fitting the criteria for any PPTF group are absent from the table despite factoring into the total study sample size
bp value for numeric variables listed is the result of unpaired, two-tailed t tests comparing the mean of naïve patients against non-naïve patients, and the p value for categorical variables has been calculated via Pearson’s chi-squared test
*Statistically significant (p < 0.05)